Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin Besse

Showing results (301-310 of 512) with videos related to

Pageof 52
Sort By:
Leukemia & Lymphoma|November 9, 2017
Next-generation sequencing discriminates myelodysplastic/myeloproliferative neoplasms from paraneoplastic leukemoid reaction in cancer patients with hyperleukocytosisRiwa Sakr, Aline Renneville, Veronique Saada, et al.
The European Respiratory Journal|January 29, 2021
Cannabis use and lung cancer: time to stop overlooking the problem?Léa Betser, Matthieu Glorion, Pierre Mordant, et al.
The Lancet Regional Health. Europe|July 23, 2024
Impact of pembrolizumab treatment duration on overall survival and prognostic factors in advanced non-small cell lung cancer: a nationwide retrospective cohort studyAdrien Rousseau, Stefan Michiels, Noémie Simon-Tillaux, et al.
JTO Clinical and Research Reports|September 30, 2021
Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung TrialJordi Remon, Benjamin Besse, Alexandra Leary, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 2, 2021
A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLCJyoti Malhotra, Petros Nikolinakos, Ticiana Leal, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 2, 2019
Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLCTodd M Bauer, Benjamin Besse, Alex Martinez-Marti, et al.
Cancer Treatment and Research Communications|July 29, 2022
Prognostic value of tumor immune biomarkers in biopsies from patients with refractory solid cancersTiphaine Lambert, Cedric Pobel, Léo Colmet-Daage, et al.
European Journal of Cancer (Oxford, England : 1990)|July 11, 2025
The correlation of liquid biopsy genomic data to radiomics in colon, pancreatic, lung and prostatic cancer patientsAntoine Italiano, Othilie Gautier, Jules Dupont, et al.
Cancers|December 17, 2024
Association of Lung Immune Prognostic Index (LIPI) with Disease Control Rate and Progression-Free Survival in Patients with Soft-Tissue Sarcoma Treated with Immunotherapy in Early-Phase TrialsMarianne Zoghbi, Brina A Patel, Matthieu Roulleaux Dugage, et al.
The Lancet. Oncology|October 28, 2017
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trialAlice T Shaw, Enriqueta Felip, Todd M Bauer, et al.
Pageof 52

Showing results (301-310 of 512) with videos related to

Sort By:
Pageof 52
Leukemia & Lymphoma|November 9, 2017
Next-generation sequencing discriminates myelodysplastic/myeloproliferative neoplasms from paraneoplastic leukemoid reaction in cancer patients with hyperleukocytosisRiwa Sakr, Aline Renneville, Veronique Saada, et al.
The European Respiratory Journal|January 29, 2021
Cannabis use and lung cancer: time to stop overlooking the problem?Léa Betser, Matthieu Glorion, Pierre Mordant, et al.
The Lancet Regional Health. Europe|July 23, 2024
Impact of pembrolizumab treatment duration on overall survival and prognostic factors in advanced non-small cell lung cancer: a nationwide retrospective cohort studyAdrien Rousseau, Stefan Michiels, Noémie Simon-Tillaux, et al.
JTO Clinical and Research Reports|September 30, 2021
Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung TrialJordi Remon, Benjamin Besse, Alexandra Leary, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 2, 2021
A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLCJyoti Malhotra, Petros Nikolinakos, Ticiana Leal, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 2, 2019
Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory SCLCTodd M Bauer, Benjamin Besse, Alex Martinez-Marti, et al.
Cancer Treatment and Research Communications|July 29, 2022
Prognostic value of tumor immune biomarkers in biopsies from patients with refractory solid cancersTiphaine Lambert, Cedric Pobel, Léo Colmet-Daage, et al.
European Journal of Cancer (Oxford, England : 1990)|July 11, 2025
The correlation of liquid biopsy genomic data to radiomics in colon, pancreatic, lung and prostatic cancer patientsAntoine Italiano, Othilie Gautier, Jules Dupont, et al.
Cancers|December 17, 2024
Association of Lung Immune Prognostic Index (LIPI) with Disease Control Rate and Progression-Free Survival in Patients with Soft-Tissue Sarcoma Treated with Immunotherapy in Early-Phase TrialsMarianne Zoghbi, Brina A Patel, Matthieu Roulleaux Dugage, et al.
The Lancet. Oncology|October 28, 2017
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trialAlice T Shaw, Enriqueta Felip, Todd M Bauer, et al.
Pageof 52